<DOC>
	<DOCNO>NCT02792114</DOCNO>
	<brief_summary>The purpose study test safety different dos specially prepared T cell collect blood . The investigator want find safe dose modify T cell patient metastatic HER2-negative breast cancer .</brief_summary>
	<brief_title>T-Cell Therapy Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Patients age ≥18 year metastatic breast cancer Karnofsky performance status ≥70 % Patients breast cancer pathologically confirm MSKCC ( pathology outside institution acceptable screen phase protocol ) define follow : HER2 negative ( case mix HER2 result , recent pathology result consider reflective active cancer consider ) Previously treat least 1 chemotherapy regimen metastatic disease document progression Expression mesothelin must confirm meet 1 follow criterion : Mesothelin expression ( &gt; 10 % tumor express mesothelin ) IHC Elevated serum SMRP level ( &gt; 0.4 nM/L ) Presence measureable evaluable disease Chemotherapy , target therapy ( tyrosine kinase inhibitor ) , radiotherapy must complete least 14 day administration Tcells . Prior immunotherapy checkpoint blockade ( i.e. , PD1 inhibitor , PDL1 inhibitor , CTL4antagonist similar agent ) must complete 1 month Tcell infusion . *Chemotherapy must complete least 7 day prior leukapheresis Any major operation must occur least 28 day study enrollment . All acute toxic effect previous radiotherapy , chemotherapy , surgical procedure must resolve grade 1 low accord CTCAE Lab requirement ( hematology ) : White blood cell ( WBC ) count ≥3000 cells/mm^3 Absolute neutrophil count ≥1500 neutrophils/mm^3 Platelet count ≥100,000 platelets/mm^3 Lab requirement ( serum chemistry ) : Bilirubin &lt; 1.5x upper limit normal ( ULN ) Serum alanine aminotransferase/serum aspartate aminotransferase ( ALT/AST ) &lt; 2.5x ULN ; patient liver metastasis , ALT/AST &lt; 5x ULN acceptable . Serum creatinine &lt; 1.5x ULN Cr &gt; 1.5x ULN , calculate clearance &gt; 60 Negative screen human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) antigen , hepatitis C virus ( HCV ) . If test perform previous 3 month , need repeat testing , long documentation result provide study site . Subjects must receive counsel sign separate inform consent form HIV testing . Subjects partner reproductive potential must agree use effective form contraception period drug administration 4 week completion last administration study drug . An effective form contraception define oral contraceptive plus 1 form barrier doublebarrier method contraception ( condom spermicide condom diaphragm ) . Subjects must able understand potential risk benefit study must able read provide write , inform consent study . Availability archival tumor tissue ( FFPE tissue block 1015 unstained slide ) Untreated active CNS metastasis ( progress require anticonvulsant corticosteroid symptomatic control ) ; patient history treat CNS metastasis eligible , provide follow criterion meet : Presence measurable evaluable disease outside CNS ; Radiographic demonstration improvement upon completion CNS direct therapy evidence interim progression completion CNSdirected therapy screen radiographic study ; Completion radiotherapy ≥8 week prior screen radiographic study ; Discontinuation corticosteroids anticonvulsant ≥4 week prior screen radiographic study . History seizure disorder Patients currently receive treatment concurrent active malignancy . Prior immunotherapy checkpoint blockade ( i.e. , PD1 inhibitor , PDL1 inhibitor , CTL4antagonist similar agent ) must complete 1 month prior Tcell infusion . Autoimmune antibodymediated disease , include limited systemic lupus erythematosus , rheumatoid arthritis , ulcerative colitis , Crohn 's disease , temporal arteritis ( patient history hypothyroidism exclude ) Clinically significant cardiac disease ( New York Heart Association class III/IV ) severe debilitate pulmonary disease Pregnant lactate woman Known active infection require antibiotic within 7 day start treatment ( Day 0 ) A requirement daily systemic corticosteroid reason requirement immunosuppressive immunomodulatory agent . Topical , nasal , inhaled steroid permit . Administration live , attenuated vaccine within 8 week start treatment ( Day 0 ) throughout study Any medical condition , opinion PI , may interfere subject 's participation compliance study Participation therapeutic research study receipt investigational drug within 30 day Tcell infusion</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>T-Cell</keyword>
	<keyword>Chimeric antigen receptor ( CAR )</keyword>
	<keyword>CAR T cell</keyword>
	<keyword>Triple-negative breast cancer</keyword>
	<keyword>Immunotherapy T-cell therapy</keyword>
	<keyword>16-040</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>CAR</keyword>
</DOC>